Sublocade® 300mg shortage update – March 2022

by | 31 Mar, 2022

“Unconstrained supplies of US-branded Sublocade® 300mg available for deliveries from week commencing 21st March.”
Sublocade® manufacturer, Indivior, has advised positive changes to the issues with supply of Sublocade 300mg strength under S19A conditions. Please refer to the official advice from Indivior, available here. Particular attention should be paid to the reduced out-of-refrigeration shelf life of the US-branded version compared to the Australian registered version (7 days cf. 28 days).

Support and advice on managing patients during this shortage is available from the manufacturer, Indivior, as well as via your local PABN, including specialist clinical support, where available.

Find your local PABN contact here.

Contact Indivior via telephone 02 9025 0200 or email

Pharmacotherapy Area-Based Networks